Siemens: smart finance to help medical technology growth

Medical technologies
Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Siemens Financial Services (SFS) has opened an Insight Paper ‘Digital Transformation in Healthcare’, which focuses on the need for investment in key medical technologies that will enable the digitalisation of global healthcare systems.

 

Medical technologies market

According to the report, the medical technologies’ market will continue to grow. The fastest growing areas are:

  • Al in Diagnostics 32.5% CAGR
  • Telemedicine 22.9%
  • Smart Hospitals 19.3% 

Smart Hospitals will reach a value of US$239.6bn from their current US$58.6bn market share, while telemedicine is expected to achieve US$392.2bn from its current US$75.3bn.

The ‘Digital Transformation in Healthcare’ report examines how smart finance for healthcare technology vendors and healthcare providers alike can build an ‘affordable and financially sustainable approach to acquiring digital and AI-driven technology’. 

The report outlines three core areas where smart finance can make investment possible:

  • Equipment and technology replacements and upgrades
  • New technology acquisitions
  • Smarter building transformations

 

Digital technology in healthcare

“The advantages of adopting digital technology are well known to healthcare businesses,” says Penny Pinnock, Business Development Manager at Siemens Financial Services UK. “Whether it’s replacing or upgrading ageing equipment to enhance diagnostic capabilities, or digitising the technology in infrastructure and buildings to drive down energy costs and emissions. By establishing a cohesive and consistent ‘digital thread’ throughout your organisation, you can ensure your system is aligned in its digital capabilities all the way along the patient pathway. Once this is established you will be able to reap the rewards of significant outcome improvements, clinical effectiveness, and cost reductions.

“Yet in reality, there are significant barriers to investing, with cost ranking as the main one. Fortunately, specialist financiers can offer expert guidance and can make purchasing technology cash-flow friendly, offering a way around limited capital budgets so providers can achieve the best possible care and outcomes for patients.”

Share

Featured Articles

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Nestlé Health Science launches nutrition initiative to counteract side effects of weight-loss drugs, including hollowed-out 'Ozempic Face'

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma

Schneider: Swathe of NHS Failing to Measure Sustainability

Sustainability